John B. Edwards, MD

Intra-Cellular Therapies, Inc., New York, New York

JCP
NNT, NNH, and LHH for Lumateperone
Original Research

March 6, 2023

The benefit-risk assessment of lumateperone was favorable as measured by number-needed-to-treat and number-needed-to-harm analyses.
Leslie Citrome, Suresh Durgam, John B. Edwards, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe